Download
s41375-020-0915-9.pdf 699,04KB
WeightNameValue
1000 Titel
  • Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
1000 Autor/in
  1. Hochhaus, Andreas |
  2. Gambacorti-Passerini, Carlo |
  3. Abboud, Camille |
  4. Gjertsen, Bjørn Tore |
  5. Brümmendorf, Tim H. |
  6. Smith, B. Douglas |
  7. Ernst, Thomas |
  8. Giraldo-Castellano, Pilar |
  9. Olsson-Strömberg, Ulla |
  10. Saussele, Susanne |
  11. Bardy-Bouxin, Nathalie |
  12. Viqueira, Andrea |
  13. Leip, Eric |
  14. Russell-Smith, T. Alexander |
  15. Leone, Jocelyn |
  16. Rosti, Gianantonio |
  17. Watts, Justin |
  18. Giles, Francis J. |
  19. Abruzzese, E. |
  20. Akard, L. P. |
  21. Bosi, A. |
  22. Cervantes, F. |
  23. Charbonnier, A. |
  24. Di Raimondo, F. |
  25. Etienne, G. |
  26. Garcia Gutierrez, V. |
  27. Guerci-Bresler, A. P. |
  28. Hjorth-Hansen, H |
  29. Karsenti, J. M. |
  30. Kelly, K. R. |
  31. Le Coutre, P. |
  32. Martinez Chamorro, C. |
  33. Oehler, V. G. |
  34. Orti Pascual, G. |
  35. Petzer, A. |
  36. Pungolino, E. |
  37. Rege-Cambrin, G. |
  38. Rigal-Huguet, F. |
  39. Roboz, G. J. |
  40. Rousselot, P. |
  41. Sanchez-Guijo, F. M. |
  42. Sanz Santillana, G. |
  43. Schafhausen, P. |
  44. Scheid, C. |
  45. Schmidt, S. |
  46. Specchia, G. |
  47. Steegmann, J. L. |
  48. Stenke, L. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-22
1000 Erschienen in
1000 Quellenangabe
  • 34(8):2125-2137
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-020-0915-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387243/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-negative/BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 year after last enrolled patient (median treatment duration 23.7 months), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 year was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major molecular response (MMR) rates by 1 year were 80.6% and 70.5%, respectively, in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 year and MMR by 1 year, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs.
1000 Sacherschließung
lokal Protein-Tyrosine Kinases/antagonists
lokal Female [MeSH]
lokal Aniline Compounds/therapeutic use [MeSH]
lokal Chronic myeloid leukaemia
lokal Aged, 80 and over [MeSH]
lokal Nitriles/therapeutic use [MeSH]
lokal Aged [MeSH]
lokal Quinolines/therapeutic use [MeSH]
lokal Adult [MeSH]
lokal Drug development
lokal Humans [MeSH]
lokal Aniline Compounds/adverse effects [MeSH]
lokal Middle Aged [MeSH]
lokal Quinolines/adverse effects [MeSH]
lokal Protein Kinase Inhibitors/therapeutic use [MeSH]
lokal Leukemia, Myeloid, Chronic-Phase/psychology [MeSH]
lokal Article
lokal Leukemia, Myeloid, Chronic-Phase/drug therapy [MeSH]
lokal Philadelphia Chromosome [MeSH]
lokal Male [MeSH]
lokal Nitriles/adverse effects [MeSH]
lokal Quality of Life [MeSH]
lokal Leukemia, Myeloid, Chronic-Phase/genetics [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SG9jaGhhdXMsIEFuZHJlYXM=|https://frl.publisso.de/adhoc/uri/R2FtYmFjb3J0aS1QYXNzZXJpbmksIENhcmxv|https://frl.publisso.de/adhoc/uri/QWJib3VkLCBDYW1pbGxl|https://frl.publisso.de/adhoc/uri/R2plcnRzZW4sIEJqw7hybiBUb3Jl|https://frl.publisso.de/adhoc/uri/QnLDvG1tZW5kb3JmLCBUaW0gSC4=|https://frl.publisso.de/adhoc/uri/U21pdGgsIEIuIERvdWdsYXM=|https://frl.publisso.de/adhoc/uri/RXJuc3QsIFRob21hcw==|https://frl.publisso.de/adhoc/uri/R2lyYWxkby1DYXN0ZWxsYW5vLCBQaWxhcg==|https://frl.publisso.de/adhoc/uri/T2xzc29uLVN0csO2bWJlcmcsIFVsbGE=|https://frl.publisso.de/adhoc/uri/U2F1c3NlbGUsIFN1c2FubmU=|https://frl.publisso.de/adhoc/uri/QmFyZHktQm91eGluLCBOYXRoYWxpZQ==|https://frl.publisso.de/adhoc/uri/VmlxdWVpcmEsIEFuZHJlYQ==|https://frl.publisso.de/adhoc/uri/TGVpcCwgRXJpYw==|https://frl.publisso.de/adhoc/uri/UnVzc2VsbC1TbWl0aCwgVC4gQWxleGFuZGVy|https://frl.publisso.de/adhoc/uri/TGVvbmUsIEpvY2VseW4=|https://frl.publisso.de/adhoc/uri/Um9zdGksIEdpYW5hbnRvbmlv|https://frl.publisso.de/adhoc/uri/V2F0dHMsIEp1c3Rpbg==|https://frl.publisso.de/adhoc/uri/R2lsZXMsIEZyYW5jaXMgSi4=|https://frl.publisso.de/adhoc/uri/QWJydXp6ZXNlLCBFLg==|https://frl.publisso.de/adhoc/uri/QWthcmQsIEwuIFAu|https://frl.publisso.de/adhoc/uri/Qm9zaSwgQS4=|https://frl.publisso.de/adhoc/uri/Q2VydmFudGVzLCBGLg==|https://frl.publisso.de/adhoc/uri/Q2hhcmJvbm5pZXIsIEEu|https://frl.publisso.de/adhoc/uri/RGkgUmFpbW9uZG8sIEYu|https://frl.publisso.de/adhoc/uri/RXRpZW5uZSwgRy4=|https://frl.publisso.de/adhoc/uri/R2FyY2lhIEd1dGllcnJleiwgVi4=|https://frl.publisso.de/adhoc/uri/R3VlcmNpLUJyZXNsZXIsIEEuIFAu|https://frl.publisso.de/adhoc/uri/SGpvcnRoLUhhbnNlbiwgSA==|https://frl.publisso.de/adhoc/uri/S2Fyc2VudGksIEouIE0u|https://frl.publisso.de/adhoc/uri/S2VsbHksIEsuIFIu|https://frl.publisso.de/adhoc/uri/TGUgQ291dHJlLCBQLg==|https://frl.publisso.de/adhoc/uri/TWFydGluZXogQ2hhbW9ycm8sIEMu|https://frl.publisso.de/adhoc/uri/T2VobGVyLCBWLiBHLg==|https://frl.publisso.de/adhoc/uri/T3J0aSBQYXNjdWFsLCBHLg==|https://frl.publisso.de/adhoc/uri/UGV0emVyLCBBLg==|https://frl.publisso.de/adhoc/uri/UHVuZ29saW5vLCBFLg==|https://frl.publisso.de/adhoc/uri/UmVnZS1DYW1icmluLCBHLg==|https://frl.publisso.de/adhoc/uri/UmlnYWwtSHVndWV0LCBGLg==|https://frl.publisso.de/adhoc/uri/Um9ib3osIEcuIEou|https://frl.publisso.de/adhoc/uri/Um91c3NlbG90LCBQLg==|https://frl.publisso.de/adhoc/uri/U2FuY2hlei1HdWlqbywgRi4gTS4=|https://frl.publisso.de/adhoc/uri/U2FueiBTYW50aWxsYW5hLCBHLg==|https://frl.publisso.de/adhoc/uri/U2NoYWZoYXVzZW4sIFAu|https://frl.publisso.de/adhoc/uri/U2NoZWlkLCBDLg==|https://frl.publisso.de/adhoc/uri/U2NobWlkdCwgUy4=|https://frl.publisso.de/adhoc/uri/U3BlY2NoaWEsIEcu|https://frl.publisso.de/adhoc/uri/U3RlZWdtYW5uLCBKLiBMLg==|https://frl.publisso.de/adhoc/uri/U3RlbmtlLCBMLg==
1000 Hinweis
  • DeepGreen-ID: 6c27701402c641e4b3f07231d36715c7 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471068.rdf
1000 Erstellt am 2023-11-18T10:42:20.276+0100
1000 Erstellt von 322
1000 beschreibt frl:6471068
1000 Zuletzt bearbeitet Fri Dec 01 13:37:06 CET 2023
1000 Objekt bearb. Fri Dec 01 13:37:06 CET 2023
1000 Vgl. frl:6471068
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471068 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source